Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and ...

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

Photoimmunotherapy with the M@P nanoplatform offers a novel approach, triggering cancer cell death and boosting immune ...

Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and ...

Developing low side-effect pyroptosis and ferroptosis inducers for cancer therapy, especially dual function inducers, is a ...

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma. (HealthDay News) — Neoantigen-targeting personalized ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

Therefore, it is desirable to perform more extensive histocompatibility testing for the most immunogenic organs, but the length of cold ischemia time an organ will tolerate limits the extent of ...